Bridgeway Capital Management LLC Decreases Stock Holdings in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Bridgeway Capital Management LLC reduced its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 35.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 184,155 shares of the specialty pharmaceutical company's stock after selling 102,500 shares during the quarter. Bridgeway Capital Management LLC owned approximately 1.31% of Cumberland Pharmaceuticals worth $436,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 8th.

Cumberland Pharmaceuticals Trading Down 10.1%

Shares of NASDAQ CPIX traded down $0.53 during midday trading on Friday, reaching $4.71. 75,889 shares of the stock were exchanged, compared to its average volume of 867,727. The company has a market capitalization of $70.47 million, a P/E ratio of -6.12 and a beta of -0.35. Cumberland Pharmaceuticals Inc. has a 52-week low of $1.04 and a 52-week high of $7.25. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The stock has a 50 day moving average price of $4.64 and a 200-day moving average price of $3.45.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Cumberland Pharmaceuticals Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.